BRPI0911350A2 - conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições. - Google Patents
conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições.Info
- Publication number
- BRPI0911350A2 BRPI0911350A2 BRPI0911350A BRPI0911350A BRPI0911350A2 BR PI0911350 A2 BRPI0911350 A2 BR PI0911350A2 BR PI0911350 A BRPI0911350 A BR PI0911350A BR PI0911350 A BRPI0911350 A BR PI0911350A BR PI0911350 A2 BRPI0911350 A2 BR PI0911350A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- risk
- reducing
- conditions
- polyethylene glycol
- Prior art date
Links
- 208000031220 Hemophilia Diseases 0.000 title 1
- 208000009292 Hemophilia A Diseases 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4754408P | 2008-04-24 | 2008-04-24 | |
| PCT/IB2009/005763 WO2009130602A2 (en) | 2008-04-24 | 2009-04-24 | Factor ix conjugates with extended half-lives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0911350A2 true BRPI0911350A2 (pt) | 2017-12-05 |
Family
ID=41171051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0911350A BRPI0911350A2 (pt) | 2008-04-24 | 2009-04-24 | conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20110183906A1 (enExample) |
| EP (1) | EP2280734B1 (enExample) |
| JP (1) | JP2011519833A (enExample) |
| KR (1) | KR20110016440A (enExample) |
| CN (1) | CN102046205A (enExample) |
| AU (1) | AU2009239641B2 (enExample) |
| BR (1) | BRPI0911350A2 (enExample) |
| CA (1) | CA2722169A1 (enExample) |
| CO (1) | CO6300965A2 (enExample) |
| CR (1) | CR11763A (enExample) |
| DK (1) | DK2280734T3 (enExample) |
| EC (1) | ECSP10010632A (enExample) |
| ES (1) | ES2466340T3 (enExample) |
| IL (1) | IL208908A0 (enExample) |
| MX (1) | MX2010011672A (enExample) |
| MY (1) | MY158228A (enExample) |
| NI (1) | NI201000177A (enExample) |
| NZ (1) | NZ588854A (enExample) |
| RU (1) | RU2496521C2 (enExample) |
| UA (1) | UA101497C2 (enExample) |
| WO (1) | WO2009130602A2 (enExample) |
| ZA (1) | ZA201007559B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
| HRP20160916T1 (hr) | 2009-07-27 | 2016-11-18 | Baxalta GmbH | Konjugati proteina za koagulaciju krvi |
| US9795683B2 (en) | 2009-07-27 | 2017-10-24 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| CA2770609A1 (en) * | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| AU2011274414B2 (en) * | 2010-07-09 | 2016-10-06 | Bioverativ Therapeutics Inc. | Factor IX polypeptides and methods of use thereof |
| SG191298A1 (en) | 2010-12-22 | 2013-07-31 | Baxter Int | Materials and methods for conjugating a water soluble fatty acid derivative to a protein |
| EP3412314A1 (en) * | 2011-05-27 | 2018-12-12 | Baxalta GmbH | Therapeutic proteins conjugated to polysialic acid and methods of preparing same |
| WO2013156488A2 (en) * | 2012-04-16 | 2013-10-24 | Leverton Licence Holdings Limited | Optimised subcutaneous therapeutic agents |
| US20150125473A1 (en) * | 2012-06-19 | 2015-05-07 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
| HK1213521A1 (zh) | 2012-09-25 | 2016-07-08 | Bioverativ Therapeutics Inc. | Fix多肽的應用 |
| TWI745671B (zh) | 2013-03-15 | 2021-11-11 | 美商百歐維拉提夫治療公司 | 因子ｉｘ多肽調配物 |
| AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
| EA038573B1 (ru) | 2014-03-24 | 2021-09-16 | Биовератив Терапьютикс Инк. | Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения |
| GB2564389A (en) | 2017-07-04 | 2019-01-16 | Green Running Ltd | A system and method for utility management |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171569A (en) | 1985-03-15 | 1992-12-15 | National Research Development Corporation | Factor IX preparations uncontaminated by plasma components or pox virus |
| US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| JP2003521930A (ja) * | 2000-02-11 | 2003-07-22 | マキシゲン・エイピーエス | 第ＶＩＩ因子または第ＶＩＩａ因子様分子 |
| WO2004060965A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| ATE399185T1 (de) * | 2002-12-31 | 2008-07-15 | Nektar Therapeutics Al Corp | Maleinsäureamid polymerderivate und ihre biokonjugate |
| EP1581582B2 (en) * | 2003-01-06 | 2017-06-07 | Nektar Therapeutics | Thiol-selective water-soluble polmer derivatives |
| GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| PL1842920T5 (pl) | 2003-09-23 | 2018-04-30 | University Of North Carolina At Chapel Hill | Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K |
| JP4855074B2 (ja) * | 2003-09-30 | 2012-01-18 | 一般財団法人化学及血清療法研究所 | 高純度血液凝固ｉｘ因子調製物およびその精製方法 |
| DE602004026897D1 (de) | 2003-10-14 | 2010-06-10 | Baxter Healthcare Sa | Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| ES2390082T5 (es) * | 2004-06-30 | 2018-01-19 | Nektar Therapeutics | Conjugados de resto de Factor IX y polímeros |
| WO2006063292A1 (en) | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| EP2295547B1 (en) | 2005-02-28 | 2017-09-20 | Baxalta GmbH | Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression |
| CA2601574C (en) | 2005-03-15 | 2014-12-02 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| JP5216580B2 (ja) * | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー／エス | グリコペグ化第ｉｘ因子 |
| MX2008012600A (es) * | 2006-03-31 | 2008-12-12 | Baxter Int | Factor viii pegilado. |
| EP2213733A3 (en) * | 2006-05-24 | 2010-12-29 | Novo Nordisk Health Care AG | Factor IX analogues having prolonged in vivo half life |
| JP5737821B2 (ja) * | 2006-08-17 | 2015-06-17 | 一夫 大橋 | 血友病ｂ治療剤及びその製造方法 |
-
2009
- 2009-04-24 CN CN200980119877XA patent/CN102046205A/zh active Pending
- 2009-04-24 WO PCT/IB2009/005763 patent/WO2009130602A2/en not_active Ceased
- 2009-04-24 BR BRPI0911350A patent/BRPI0911350A2/pt not_active IP Right Cessation
- 2009-04-24 UA UAA201013989A patent/UA101497C2/ru unknown
- 2009-04-24 NZ NZ588854A patent/NZ588854A/en not_active IP Right Cessation
- 2009-04-24 DK DK09734192.9T patent/DK2280734T3/da active
- 2009-04-24 MX MX2010011672A patent/MX2010011672A/es active IP Right Grant
- 2009-04-24 EP EP09734192.9A patent/EP2280734B1/en not_active Not-in-force
- 2009-04-24 US US12/989,555 patent/US20110183906A1/en not_active Abandoned
- 2009-04-24 MY MYPI2010004993A patent/MY158228A/en unknown
- 2009-04-24 AU AU2009239641A patent/AU2009239641B2/en not_active Ceased
- 2009-04-24 ES ES09734192.9T patent/ES2466340T3/es active Active
- 2009-04-24 KR KR1020107026368A patent/KR20110016440A/ko not_active Ceased
- 2009-04-24 CA CA2722169A patent/CA2722169A1/en not_active Abandoned
- 2009-04-24 JP JP2011505616A patent/JP2011519833A/ja active Pending
- 2009-04-24 RU RU2010147813/15A patent/RU2496521C2/ru not_active IP Right Cessation
-
2010
- 2010-10-22 NI NI201000177A patent/NI201000177A/es unknown
- 2010-10-22 ZA ZA2010/07559A patent/ZA201007559B/en unknown
- 2010-10-24 IL IL208908A patent/IL208908A0/en unknown
- 2010-10-27 CR CR11763A patent/CR11763A/es not_active Application Discontinuation
- 2010-11-24 EC EC2010010632A patent/ECSP10010632A/es unknown
- 2010-11-24 CO CO10147494A patent/CO6300965A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK2280734T3 (da) | 2014-05-26 |
| UA101497C2 (ru) | 2013-04-10 |
| WO2009130602A3 (en) | 2010-02-11 |
| MX2010011672A (es) | 2011-03-02 |
| CO6300965A2 (es) | 2011-07-21 |
| HK1151986A1 (en) | 2012-02-17 |
| US20110183906A1 (en) | 2011-07-28 |
| RU2010147813A (ru) | 2012-05-27 |
| WO2009130602A9 (en) | 2010-04-22 |
| ZA201007559B (en) | 2012-01-25 |
| AU2009239641A1 (en) | 2009-10-29 |
| JP2011519833A (ja) | 2011-07-14 |
| AU2009239641B2 (en) | 2013-11-07 |
| ES2466340T3 (es) | 2014-06-10 |
| WO2009130602A2 (en) | 2009-10-29 |
| RU2496521C2 (ru) | 2013-10-27 |
| MY158228A (en) | 2016-09-15 |
| IL208908A0 (en) | 2011-01-31 |
| ECSP10010632A (es) | 2011-02-28 |
| EP2280734B1 (en) | 2014-02-26 |
| CA2722169A1 (en) | 2009-10-29 |
| CN102046205A (zh) | 2011-05-04 |
| NI201000177A (es) | 2011-08-29 |
| NZ588854A (en) | 2011-12-22 |
| KR20110016440A (ko) | 2011-02-17 |
| CR11763A (es) | 2011-04-26 |
| EP2280734A2 (en) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0911350A2 (pt) | conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições. | |
| BRPI0819842A2 (pt) | Sistema de carga e método para operar o mesmo. | |
| BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BRPI1006145A2 (pt) | "composição e método para tratamento de diabetes". | |
| BRPI1011760A2 (pt) | método para prevenir ou reduzir coagulação no trato gastrointestinal superior de um indivíduo, e, uso de proteína anticoagulante. | |
| BRPI0820843A2 (pt) | Sistema de monitoração de eletrocardiograma, e, método para operar o mesmo | |
| BRPI0922122A2 (pt) | composições e métodos para tratamento de doença celíaca. | |
| BRPI0813757A2 (pt) | Sistema de implante, e, método | |
| BRPI0716439A2 (pt) | formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas. | |
| BRPI0920443A2 (pt) | compostos de piperazina, agente, e, processo para combater vegetacao indesejavel. | |
| BRPI0717219A2 (pt) | "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica." | |
| BRPI0822633A2 (pt) | Desinfetante, e, método de esterilização. | |
| BRPI0911757A2 (pt) | composiÇÕes e mÉtodos para tratar distérbios digestivos. | |
| BRPI0718688A2 (pt) | Composições de baixa irritação e métodos para preparar as mesmas. | |
| BRPI1016158A2 (pt) | "sistema e método para monitorar um desempenho atlético, e, sistema e método de monitoramento do desempenho atlético." | |
| BRPI0822756A2 (pt) | sistema de prótese de válvula cardíaca e processo para produzir prótese de válvula cardíaca. | |
| BRPI0822078A2 (pt) | Método, e, sistema. | |
| MX379016B (es) | Composiciones y metodos para tratar enfermedad de gaucher. | |
| BR112012004333A2 (pt) | composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio. | |
| HRP20181727T1 (hr) | Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška | |
| BRPI0916593A2 (pt) | processo para modificação contínua de gesso diidratado e gesso diidratado modificado obtido através do processo. | |
| BRPI0816175A2 (pt) | Composições adequadas para tratamento de doença, distúrbio ou condição da espinha. | |
| BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. | |
| BRPI0915382A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), C12N 9/64 (2006.01), A61P 7/ |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B25B | Requested transfer of rights rejected |
Owner name: CELTIC PHARMA PEG LTD. (BM) |